We're building a better ClinicalTrials.gov. Check it out and tell us what you think!

Working…

ClinicalTrials.gov Menu

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03383575

Recruitment Status : Recruiting

First Posted : December 26, 2017

Last Update Posted : March 14, 2023

See Contacts and Locations

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

National Cancer Institute (NCI)

Celgene

Information provided by (Responsible Party):

M.D. Anderson Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	February 28, 2025
Estimated Study Completion Date :	February 28, 2025

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

DiNardo CD, Venugopal S, Lachowiez CA, Takahashi K, Loghavi S, Montalban-Bravo G, Wang X, Carraway HE, Sekeres MA, Sukkur A, Hammond D, Chien KS, Maiti A, Masarova L, Sasaki K, Alvarado Y, Kadia TM, Short NJ, Daver NG, Borthakur G, Ravandi F, Kantarjian HM, Patel BJ, DeZern AE, Roboz GJ, Garcia-Manero G. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv. 2022 Aug 16:bloodadvances.2022008378. doi: 10.1182/bloodadvances.2022008378. Online ahead of print.